<source id="3oodw" ><sup id="3oodw" ></sup></source>

      1. <s id="3oodw" ><th id="3oodw" ><small id="3oodw" ></small></th></s>
        <i id="3oodw" ><optgroup id="3oodw" ></optgroup></i>

            <input id="3oodw" ><bdo id="3oodw" ><cite id="3oodw" ></cite></bdo></input>
            <delect id="3oodw" ><ruby id="3oodw" ></ruby></delect>

            <em id="3oodw" ><progress id="3oodw" ></progress></em><input id="3oodw" ></input>
            <strike id="3oodw" ></strike>
            India

            Japan: Generics and Off-Patent Medicines

            Sandoz Completes Acquisition of Aspen’s Japanese Operations

            | Editor: Alexander Stark

            Sandoz is strengthening its position in Japan, the world’s third largest market for generics and off-patent medicines.
            Gallery: 1 image
            Sandoz is strengthening its position in Japan, the world’s third largest market for generics and off-patent medicines. (Source: Public Domain / )

            Sandoz announced the successful acquisition of Aspen’s Japanese operations and assets. The transaction is to reinforce the company's strategic focus on Japan, the world’s third largest market for generics and off-patent medicines.

            Holzkirchen/Germany – Sandoz announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Sandoz has acquired all of the shares in Aspen Japan K.K. and associated assets held by AGI.

            The acquisition enables the company to expand its presence in Japan’s marketplace, the third largest for generics and off-patent medicines worldwide. It also strengthens their presence in the hospital channel by complementing the portfolio and pipeline of hospital generic and biosimilar products in Japan with a dedicated sales, marketing and medical organization.

            Comments are being loaded ....

            Leave a comment

            The comment is checked by an editor and will be released soon.

            1. Avatar
              Avatar
              Edited by at
              Edited by at
              1. Avatar
                Avatar
                Edited by at
                Edited by at

            Comments are being loaded ....

            Report comment

            Kommentar Freigeben

            Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

            Freigabe entfernen

            Der untenstehende Text wird an den Kommentator gesendet, falls dieser eine Email-hinterlegt hat.

            copyright

            This article is protected by copyright. You want to use it for your own purpose? Contact us via: (ID: 46342723 / Pharma & Food)